NCT01988831

Efficacy of Propranolol Treatment to Prevent Melanoma Progression

Phase 2 Prospective Study of the Efficacy of Propranolol on Malignant Melanoma Progression. A Randomized Placebo-controlled,Single Blind Trial

• Status: Suspended
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 450 (estimated)
• Sponsor: University Hospital, Geneva · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Melanoma's incidence is increasing worldwide. The efforts made in melanoma screening led to an earlier detection of the primary tumour and a better prognosis, but melanoma remains an aggressive cancer when it comes to its metastatic stage. Three recent retrospective studies compared groups of patients diagnosed with primary melanoma and treated with betablockers for another indication to patients who never received betablockers. In these three studies, the outcome of the disease is significantly better for people under betablocker treatment with a decreased rate of recurrence and a better 5 years survival rate. Here we want to investigate the efficacy and the tolerability of an adjuvant treatment with propranolol for patients suffering from a primary melanoma with a high risk of recurrence.

Conditions

• Stages III Skin Melanoma
• Stages II Skin Melanoma
• Stage IB Skin Melanoma

Interventions

Type	Name	Description
DRUG	Propranolol hydrochloride	This intervention apply to Propranolol group
DRUG	Placebo pill	We use placebo pills alike propranolol commercial pills to ensure blindness of the subjects during the study.

Timeline

• Start date: 2016-06-01
• Primary completion: 2022-01-01
• Completion: 2022-03-01
• First posted: 2013-11-20
• Last updated: 2019-05-10

Locations

1 site across 1 country: Switzerland